CIK 0001885522 · Non-accelerated filer<br>Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844367680
- Phone
- (857) 760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $481,506
- in 2 filings
Net −$481,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-13 | Halawa Alaa Director | Grant or award · Stock Option (Right to Buy) | +46,455 | 46,455 | ||
| 2025-02-13 | Halawa Alaa Director | Grant or award · Stock Option (Right to Buy) | +28,571 | 28,571 | ||
| 2025-02-13 | Burow Kristina Director | Returned to the company · Stock Option (Right to Buy) | −46,455 | 0 | ||
| 2025-02-13 | Burow Kristina Director | Returned to the company · Stock Option (Right to Buy) | −28,571 | 0 | ||
| 2025-02-13 | Burow Kristina Director | Grant or award · Stock Option (Right to Buy) | +46,455 | 46,455 | ||
| 2025-02-13 | Burow Kristina Director | Grant or award · Stock Option (Right to Buy) | +28,571 | 28,571 | ||
| 2025-02-13 | Duncan Jason See Remarks | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2025-02-13 | Duncan Jason See Remarks | Returned to the company · Stock Option (Right to Buy) | −400,000 | 0 | ||
| 2025-02-13 | Duncan Jason See Remarks | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-12-27 | BERNS PAUL L Director | Gift | −133,097 | 7,685,069 | ||
| 2024-12-27 | BERNS PAUL L Director | Gift | −133,097 | 7,551,972 | ||
| 2024-12-27 | BERNS PAUL L Director | Gift | −133,097 | 7,418,875 | ||
| 2024-10-18 | Fust Matthew K Director | Option exercise 10b5-1 | +6,205 | $8.79 | $55K | 26,305 |
| 2024-10-18 | Fust Matthew K Director | Option exercise 10b5-1 | +7,844 | $2.52 | $20K | 34,149 |
| 2024-10-18 | Fust Matthew K Director | Sale 10b5-1 | −14,049 | $17.03 | $239K | 20,100 |
| 2024-10-18 | Fust Matthew K Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,205 | 0 | ||
| 2024-10-18 | Fust Matthew K Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,844 | 85,586 | ||
| 2024-10-17 | Fust Matthew K Director | Option exercise 10b5-1 | +3,783 | $8.32 | $31K | 23,883 |
| 2024-10-17 | Fust Matthew K Director | Option exercise 10b5-1 | +1,800 | $8.79 | $16K | 25,683 |
| 2024-10-17 | Fust Matthew K Director | Option exercise 10b5-1 | +2,156 | $2.52 | $5K | 27,839 |
Page 12 of 20 · 384 trades